Free Trial

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech logo
$98.37 -0.89 (-0.90%)
As of 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
12

Based on 16 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, and 12 have given a buy rating for BNTX.

Consensus Price Target

$134.97
36.96% Upside
According to the 16 analysts' twelve-month price targets for BioNTech, the average price target is $134.97. The highest price target for BNTX is $171.44, while the lowest price target for BNTX is $110.00. The average price target represents a forecasted upside of 36.96% from the current price of $98.54.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Analyst Ratings Over Time

TypeCurrent Forecast
9/17/24 to 9/17/25
1 Month Ago
8/18/24 to 8/18/25
3 Months Ago
6/19/24 to 6/19/25
1 Year Ago
9/18/23 to 9/17/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$134.97$135.80$137.86$118.00
Forecasted Upside36.96% Upside20.66% Upside32.05% Upside-5.38% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside35.97% Upside17,135.82% Upside11.50% Upside
News Sentiment Rating
Positive News

See Recent BNTX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/8/2025HC Wainwright
1 of 5 stars
Robert Burns
1 of 5 stars
Reiterated RatingBuy$136.00+20.93%
8/5/2025Bank of America
4 of 5 stars
Tazeen Ahmad
Not Rated
Boost TargetBuy$126.00 ➝ $134.00+21.78%
8/5/2025Wells Fargo & Company
3 of 5 stars
Mohit Bansal
Not Rated
Set TargetOverweight$170.00 ➝ $150.00+36.32%
7/10/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$132.00 ➝ $133.00+18.45%
6/3/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00 ➝ $155.00+33.39%
6/2/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$112.00+2.47%
5/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuyNeutral$110.00+12.79%
5/22/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$120.00 ➝ $116.00+17.24%
5/6/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00 ➝ $140.00+38.48%
3/11/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$171.44 ➝ $171.44+65.58%
3/11/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$130.00 ➝ $143.00+35.74%
11/19/2024Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$130.00+27.61%
11/19/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeIn-LineOutperform$110.00 ➝ $125.00+22.71%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetHold$132.00 ➝ $122.00+10.28%
10/7/2024HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$97.00 ➝ $136.00+10.88%
9/19/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$95.00 ➝ $150.00+33.87%
9/18/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$97.00 ➝ $131.00+5.04%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$96.00 ➝ $150.00+21.49%
8/2/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:38 PM ET.


Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 16, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BioNTech SE:

  • The current stock price is around $96.74, which may present a buying opportunity for investors looking for potential growth.
  • BioNTech SE has shown impressive revenue growth, with a quarterly revenue increase of over 100% compared to the same period last year, indicating strong demand for its products.
  • Thirteen investment analysts have rated BioNTech SE with a Buy rating, suggesting a positive outlook from market experts.
  • The company has a solid market capitalization of approximately $23.26 billion, reflecting its significant presence in the biotechnology sector.
  • BioNTech SE is actively developing immunotherapies for cancer and infectious diseases, positioning itself in a high-demand and innovative field.

BioNTech
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The company reported a loss of $1.60 EPS for the latest quarter, missing analysts' expectations, which may raise concerns about its profitability.
  • BioNTech SE has a negative net margin, indicating that it is currently spending more than it earns, which could be a red flag for potential investors.
  • The stock has a high beta of 1.39, suggesting that it is more volatile than the market, which could lead to greater risk for investors.
  • Analysts forecast a negative EPS of -3.88 for the current fiscal year, indicating ongoing challenges in achieving profitability.
  • Only 15.52% of the stock is owned by institutional investors, which may suggest a lack of confidence from larger investment firms.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $134.97, with a high forecast of $171.44 and a low forecast of $110.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 36.96% based on their 12-month stock forecasts.

BioNTech has been rated by research analysts at Bank of America, HC Wainwright, Morgan Stanley, and Wells Fargo & Company in the past 90 days.

Analysts like BioNTech less than other "medical" companies. The consensus rating score for BioNTech is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how BNTX compares to other companies.


This page (NASDAQ:BNTX) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners